Logo image of ONCY

ONCOLYTICS BIOTECH INC (ONCY) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ONCY - CA6823108759 - Common Stock

0.8871 USD
-0.02 (-2.02%)
Last: 12/30/2025, 4:30:02 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ONCY. ONCY was compared to 530 industry peers in the Biotechnology industry. Both the profitability and financial health of ONCY have multiple concerns. ONCY is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ONCY has reported negative net income.
ONCY had a negative operating cash flow in the past year.
In the past 5 years ONCY always reported negative net income.
In the past 5 years ONCY always reported negative operating cash flow.
ONCY Yearly Net Income VS EBIT VS OCF VS FCFONCY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

The Return On Assets of ONCY (-152.26%) is worse than 86.04% of its industry peers.
ONCY has a worse Return On Equity (-499.46%) than 76.04% of its industry peers.
Industry RankSector Rank
ROA -152.26%
ROE -499.46%
ROIC N/A
ROA(3y)-98.37%
ROA(5y)-83.59%
ROE(3y)-241.47%
ROE(5y)-177.64%
ROIC(3y)N/A
ROIC(5y)N/A
ONCY Yearly ROA, ROE, ROICONCY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K 20K 30K

1.3 Margins

ONCY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ONCY Yearly Profit, Operating, Gross MarginsONCY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, ONCY has more shares outstanding
The number of shares outstanding for ONCY has been increased compared to 5 years ago.
ONCY has a worse debt/assets ratio than last year.
ONCY Yearly Shares OutstandingONCY Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ONCY Yearly Total Debt VS Total AssetsONCY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -33.55, we must say that ONCY is in the distress zone and has some risk of bankruptcy.
ONCY's Altman-Z score of -33.55 is on the low side compared to the rest of the industry. ONCY is outperformed by 90.38% of its industry peers.
ONCY has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
ONCY has a Debt to Equity ratio of 0.10. This is in the lower half of the industry: ONCY underperforms 63.40% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z -33.55
ROIC/WACCN/A
WACCN/A
ONCY Yearly LT Debt VS Equity VS FCFONCY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

A Current Ratio of 2.88 indicates that ONCY has no problem at all paying its short term obligations.
ONCY's Current ratio of 2.88 is on the low side compared to the rest of the industry. ONCY is outperformed by 65.85% of its industry peers.
ONCY has a Quick Ratio of 2.88. This indicates that ONCY is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.88, ONCY is doing worse than 63.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.88
Quick Ratio 2.88
ONCY Yearly Current Assets VS Current LiabilitesONCY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

ONCY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.36%.
EPS 1Y (TTM)-8.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 37.86% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y21.99%
EPS Next 2Y6.67%
EPS Next 3Y10.11%
EPS Next 5Y37.86%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ONCY Yearly Revenue VS EstimatesONCY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
ONCY Yearly EPS VS EstimatesONCY Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ONCY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ONCY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ONCY Price Earnings VS Forward Price EarningsONCY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ONCY Per share dataONCY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.67%
EPS Next 3Y10.11%

More info and screens

0

5. Dividend

5.1 Amount

ONCY does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ONCOLYTICS BIOTECH INC

NASDAQ:ONCY (12/30/2025, 4:30:02 PM)

0.8871

-0.02 (-2.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-05 2026-03-05/amc
Inst Owners2.87%
Inst Owner Change88.83%
Ins Owners3.42%
Ins Owner ChangeN/A
Market Cap86.41M
Revenue(TTM)N/A
Net Income(TTM)-30.41M
Analysts77.5
Price Target3.32 (274.25%)
Short Float %3.78%
Short Ratio4.7
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.91%
Min EPS beat(2)20.79%
Max EPS beat(2)35.03%
EPS beat(4)3
Avg EPS beat(4)14.8%
Min EPS beat(4)-15.35%
Max EPS beat(4)35.03%
EPS beat(8)6
Avg EPS beat(8)14.12%
EPS beat(12)8
Avg EPS beat(12)8.97%
EPS beat(16)11
Avg EPS beat(16)10.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 19.43
P/tB 19.43
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)-0.26
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS0
BVpS0.05
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -152.26%
ROE -499.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-98.37%
ROA(5y)-83.59%
ROE(3y)-241.47%
ROE(5y)-177.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.64%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.88
Quick Ratio 2.88
Altman-Z -33.55
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)24.58%
Cap/Depr(5y)28.97%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.74%
EPS Next Y21.99%
EPS Next 2Y6.67%
EPS Next 3Y10.11%
EPS Next 5Y37.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-63.16%
EBIT Next 3Y5.76%
EBIT Next 5Y8.3%
FCF growth 1Y6.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.92%
OCF growth 3YN/A
OCF growth 5YN/A

ONCOLYTICS BIOTECH INC / ONCY FAQ

Can you provide the ChartMill fundamental rating for ONCOLYTICS BIOTECH INC?

ChartMill assigns a fundamental rating of 1 / 10 to ONCY.


Can you provide the valuation status for ONCOLYTICS BIOTECH INC?

ChartMill assigns a valuation rating of 0 / 10 to ONCOLYTICS BIOTECH INC (ONCY). This can be considered as Overvalued.


How profitable is ONCOLYTICS BIOTECH INC (ONCY) stock?

ONCOLYTICS BIOTECH INC (ONCY) has a profitability rating of 0 / 10.


What is the expected EPS growth for ONCOLYTICS BIOTECH INC (ONCY) stock?

The Earnings per Share (EPS) of ONCOLYTICS BIOTECH INC (ONCY) is expected to grow by 21.99% in the next year.